Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder affecting 1:3500 male births. 1 It is characterized by a progressive loss of muscle mass and replacement of myofibres with connective and adipose tissue. The severe myopathy observed in DMD patients is due to the complete absence or substantial reduction of dystrophin at the sarcolemma of the muscle fibres. This is caused by mutations in the dystrophin gene that alter the open-reading frame of dystrophin. 2 The 427 kDa skeletal form of dystrophin has 3685 amino-acid residues and contains several domains: the amino-terminus domain that binds cytoskeletal actin filaments, a large rod-shaped domain formed by 24 repeat sequences that are predicted to adopt a triple helical conformation with four hinges and a carboxyl-terminus domain that binds a whole complex of dystrophin-associated proteins at the sarcolemma. 3 By binding to b-dystroglycan at the membrane, dystrophin acts as a physical link between the cytoskeleton and the extracellular matrix. An allelic form of this disease, Becker muscular dystrophy (BMD), is associated with an internally deleted dystrophin molecule due to mutations that maintain the reading frame. 2 This milder form of dystrophy is characterized by a later onset and a slower progression of muscle degeneration.
An animal model for DMD is the mdx mouse whose mutation in exon 23 in the murine dystrophin gene results in a premature stop codon 4 and so the full-length 427 kDa muscle isoform of dystrophin is not produced. However, the other isoforms produced from different promoters 3 0 of the point mutation are unaffected ( Figure  1 ). Despite the lack of dystrophin in the mdx muscle, some fibres show dystrophin staining at the sarcolemma. The number of these so-called revertant fibres is low, normally present at around 1% of total fibres, 5 although their number increases with the age of the mice. 6 There are many strategies for the induction of de novo dystrophin expression as a therapeutic approach for the treatment of DMD. These include systemic drug delivery, 7 gene modification at DNA and RNA levels, [8] [9] [10] [11] cell transplantation [12] [13] [14] and gene delivery with a wide range of both viral [15] [16] [17] and nonviral [18] [19] [20] delivery systems. However, therapeutic levels, together with a stable longterm presence of dystrophin at the sarcolemma of the muscle fibres, are essential. One major factor that could jeopardize the long-term persistence of dystrophin is an immune response directed against the genetically modified fibre. It has been suggested that the introduction of the complete dystrophin would act as a neoantigen, as the DMD patient's immune system would not have seen some, or all, of the epitopes present in the fulllength protein. 21 Immune responses to dystrophin have been reported in early myoblast transfer experiments, where only transient expression of dystrophin was achieved. 22 The delivery of dystrophin with viral vectors to animal models has also shown short-term expression of dystrophin in muscle fibres, 23 unless an immunosuppressive regime was used. 24 In most cases, it was not clear if the immune response was directed to the transgene itself or if this immune response was enhanced due to the vector system used, that is, cellular components or viral coat proteins. We and others have demonstrated that following the direct intramuscular injection of naked plasmid DNA expressing dystrophin in the mdx mouse, an immune response leads to a loss of fibres transfected with human dystrophin by 8 weeks postinjection, 18, 19 but no immune response to murine dystrophin was detectable by 12 weeks. 18 However, the overall numbers of dystrophin-positive fibres obtained by direct intramuscular injection of plasmid DNA was very low and so there was a formal possibility that the expression of greater amounts of antigen could break the tolerance observed in this experiment. In the current study, plasmid DNA encoding full-length murine or human dystrophin driven by the CMV promoter was electroporated into the tibialis anterior (TA) muscles of mdx mice 2 h after treatment with hyaluronidase, as this procedure has been shown to achieve high transfection efficiencies in muscle. 20, 25 We also investigated whether revertant fibres and/or expression of different dystrophin isoforms contribute to the tolerance to murine dystrophin. The role of the other smaller isoforms of dystrophin in inducing tolerance was examined in mdx3cv mice, a strain of the mdx mouse with a mutation in exon 65 and that does not produce any of the dystrophin isoforms. 26 To investigate as to how much of the human dystrophin molecule is required to provide tolerance to de novo expression of full-length human dystrophin, we examined immune responses to electrotransfer of a human dystrophin construct into mdx transgenic lines expressing a range of internally deleted recombinant human dystrophin molecules.
Results

Analysis of the microdystrophin transgenic mdx line
The microdystrophin transgenic line expresses a human microdystrophin with deletion of exons 13-48 ( Figure 1 ) compared to the deletion of exons 17-48 in the previously published minidystrophin transgenic line (AB2). 27 Western blot analysis of skeletal muscle RIPA buffer preparations from this microdystrophin transgenic mdx line, control C57Bl10 and minidystrophin mice indicate equivalent total dystrophin expression levels in the minidystrophin and microdystrophin transgenic lines (Figure 2a, left panel) . Staining with the human specific antibody Dy10/12B2 confirms the species of dystrophin expressed in the microdystrophin line (Figure 2a, right panel) . In addition to the sarcolemmalassociated stain, there was a degree of perinuclear stain, suggesting that the recombinant dystrophin was not being efficiently translocated to the membrane. The microdystrophin transgenic line has a moderate dystrophic phenotype with regions in which myofibres show centrally placed myonuclei on haematoxylin and eosin staining, indicating previous rounds of muscle degeneration and regeneration (Figure 2b ). The microdystrophin line shows a level of dystrophin expression at the sarcolemma similar to that seen in the minidystrophin line when using rabbit polyclonal DysC3750 over a range of dilutions. 20, 28 As shown in Figure 2b , at a dilution of 1:2000, the endogenous signal in the C57/Bl10 wild-type mouse tissue and in revertant fibres in the mdx is still clearly visible, but staining of the transgene product is not detectable in the transgenic line (Figure 2b ).
Does the hyaluronidase and electrotransfer procedure increase the number of revertant fibres?
In our analysis of the number of dystrophin-positive fibres following gene transfer in the injected leg, we subtract the number of revertant fibres in the control uninjected leg. To investigate whether the plasmid electrotransfer procedure per se increases the number of revertant fibres in the injected leg, 13-to 14-week-old mdx mice were subjected to the following treatments: preinjection of saline (n ¼ 9) or preinjection of saline followed by electrotransfer of either saline (n ¼ 4) or CMV0 plasmid (n ¼ 5), preinjection of hyaluronidase (n ¼ 9) or preinjection of hyaluronidase followed by electrotransfer of either saline (n ¼ 4) or CMV0 plasmid (n ¼ 5). The revertant fibre counts show that there were no significant differences between any of the groups; however, the trend shows a decrease in the number of revertant fibres in the electroporated legs compared to the nonelectroporated ones ( Figure 3 ).
Electrotransfer of human and murine full-length dystrophin constructs into mdx and mdx3cv mice Immune responses to the expression of dystrophin were assessed after hyaluronidase pretreatment and electrotransfer of plasmid DNAs encoding full-length human or murine dystrophin. Mdx mice (11 week old) were injected in the right TA with either human (CDF) or , indicates the start of the sequence overlap present in the indicated dystrophin isoforms expressed from internal promoters; *, indicates the site of the point mutation in the mdx mouse; #, indicates the site of the point mutation in the mdx3cv mouse.
Long-term expression of full-length human dystrophin in mdx mice A Ferrer et al murine (CMVmoDys) dystrophin-encoding plasmids. The control left TA was injected with the noncoding plasmid CMV0. Mice were killed 1 or 8 weeks postplasmid injection and TA sections were stained for dystrophin expression using DysC3750 at 1:2000. At 1 week postinjection, mice injected with either construct showed similar numbers of dystrophin-positive fibres (Figure 4a and b) . However, by 8 weeks postinjection, the number of human dystrophin-positive fibres had dropped significantly (Po0.001, Figure 4b ), consistent with our previously reported data for intramuscular injection of plasmid DNA, 18 whereas no difference was found in the number of murine dystrophin-expressing fibres between both time points (Figure 4a ). At 8 weeks postinjection of murine dystrophin, there was a nonsignificant increase in CD8 þ infiltrate in the treated mdx muscle (51.6749.4 additional CD8 þ cells per mm . Despite the higher number of fibres transfected with murine dystrophin after the combined hyaluronidase and electrotransfer procedure compared with multiple direct injection, 18 only a very low level of antibodies against murine dystrophin was detected by Western blot analysis when the murine dystrophin construct was 
Figure 3
Graph showing the maximum number of revertant fibres detected in transverse sections of mdx TA muscle subjected to different variants of the hyaluronidase plus electrotransfer procedure. Each bar represents the mean7s.e.m. Stippled white bar shows saline preinjection, n ¼ 9; stippled grey bar shows saline preinjection þ saline electrotransfer, n ¼ 4; stippled black bar shows saline preinjection þ CMV0 electrotransfer, n ¼ 5; white bar shows hyaluronidase preinjection, n ¼ 9; grey bar shows hyaluronidase preinjection þ saline electrotransfer, n ¼ 4; and the black bar shows hyaluronidase preinjection þ CMV0 electrotransfer, n ¼ 5. There are no significant differences between any of the groups. , respectively. 6C5 is the control antidystrophin monoclonal antibody Dy8/6C5. There is a strong humoral response to human dystrophin and a very weak response to murine dystrophin. Blots were simultaneously probed with a monoclonal antibody recognizing metavinculin and vinculin as a loading control.
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A Ferrer et al injected into mdx mice ( Figure 4c ). However, a marked antibody response to dystrophin was found in the sera from mdx mice injected with human dystrophin plasmid CDF ( Figure 4d ). This response is dystrophin specific as these antibodies bind to dystrophin in the human dystrophin positive AD17 lysate, but not to the mdx lysate.
We also examined the number of murine dystrophinpositive fibres after electrotransfer of CMVmoDys into the TA muscles of 9-week-old mdx3cv mice. In this and consecutive experiments, the left leg was left untreated. As previously seen in the mdx mice, there was no significant difference in the number of murine dystrophin-positive fibres present in the muscle of mdx3cv mice at 1 and 8 weeks postinjection ( Figure 5 ). The muscles from the mdx3cv mice presented a very small increase in CD8 þ infiltrate compared to the uninjected leg (3.872.9 additional CD8 þ cells per mm 2 ), and there was no evidence of clustering specific to murine dystrophintransfected fibres. No antibody response to murine dystrophin was detected in the treated mice (data not shown).
Direct injection of human full-length dystrophin into transgenic mdx mice expressing human recombinant mini-dystrophin
The transgenic line AB2 expresses human minidystrophin, with deletions of exons 17-48 that encode part of the rod domain. Minidystrophin transgenics and mdx littermates (6 to 11 weeks old) received one dose of human full-length plasmid (PTG11025) in muscles treated previously with BaCl 2 to induce muscle regeneration and so enhance plasmid gene transfer. At 8 weeks after the injection of the full-length human plasmid, there were dystrophin-positive fibres present in the transgenic muscles, whereas there was a significantly lower number of dystrophin-transfected fibres in the mdx nontransgenic littermates (P ¼ 0.048, Figure 6 ). ) was not significantly different, but both were significantly higher than the levels in the contralateral untreated muscles (P ¼ 0.001).
Western blot analysis against human dystrophin protein extracts demonstrated no antidystrophin antibodies in the serum from transgenic mice, but mdx littermates exhibited a clear antibody response to dystrophin very similar to that shown in Figure 4d (data not shown).
Electrotransfer of human full-length dystrophin constructs into transgenic mdx mice expressing human recombinant microdystrophin Human full-length plasmid CDF was electroporated into the left TA of a group of 14-19-week-old microdystrophin transgenic mice and mdx littermates leaving the right leg uninjected. At 8 weeks after injection, a significantly higher number of dystrophin-positive fibres were present in the injected muscles of the microdystrophin transgenics compared to the number of positive fibres observed in the mdx nontransgenic littermates (P ¼ 0.001, Figure 7a) .
The experiment was repeated in 18-to 19-week-old microdystrophin transgenic mice and mdx littermates. An average of over 200 dystrophin-positive fibres was present in the TA muscles of microdystrophin transgenic mice 8 weeks postinjection, with dramatically fewer dystrophin-positive fibres observed in nontransgenic mdx littermates (P ¼ 0.001, Figure 7b ).
All muscles from the microdystrophin transgenic mice showed a very low degree of CD8 þ infiltrate, whereas mdx mice showed a slightly higher degree of CD8 þ cells. In experiment 1, this difference was significant 2 in the mdx littermates). A faint antidystrophin antibody response was detected in the serum from the microdystrophin transgenics in the first experiment (data not shown), but no response was noted in the transgenics in the second experiment ( Figure  7c ). In contrast, a very strong antibody titre was present in the serum from mdx littermates (Figure 7c ).
Discussion
A number of treatments aimed at correcting the dystrophic phenotype have been developed. One promising approach is the introduction of a functional copy of the dystrophin gene that expresses the protein at therapeutic levels. Transgenic mice expressing human 27 or murine 29 dystrophin cDNAs have shown that expression of the transgene at levels equivalent to 20-30% of endogenous dystrophin at the sarcolemma can correct the myopathic phenotype.
Although the expression of a Becker-like minidystrophin gene can restore the normal phenotype in transgenic mdx muscle, ideally gene therapy for DMD should involve the delivery of the full-length DNA. For example, nNOS localization to the sarcolemma requires elements of the rod domain that are missing in the recombinant minidystrophin. 30, 31 Plasmid DNA is able to accommodate the 14 kb full-length cDNA and has been used to deliver the dystrophin gene into the muscles of mdx mice, 18, 32, 33 although with a low efficiency. Recently, the use of electroporation to introduce plasmids into muscle has increased gene transfer efficiency, 25 including delivery of full-length dystrophin into the skeletal muscle of mdx mice. 20, 34, 35 For viral-based delivery, adenoviral vectors have been engineered with deletion of all viral sequences, except for those required for packaging of the virus. These so-called 'gutted' adenoviruses have a high cloning capacity and are able to accommodate the full-length dystrophin cDNA. They have successfully delivered human 16 and mouse 16, 17 full-length dystrophin into the mdx muscle achieving very high levels of transfection and improved muscle function.
We have previously shown that there is destruction of the muscle fibres expressing human full-length in the mdx mouse but not in the immunodeficient mdx/nude mouse. 18 Dystrophin is a structural protein present in the inner part of the muscle sarcolemma, so it is unlikely that circulating antibodies could bind to dystrophin and destroy an otherwise intact muscle fibre. A cytotoxic T-cell response is a more likely mechanism as the destruction of muscle fibres seen in the mdx mouse was not seen in the T-cell-deficient mdx/nude mouse. Indeed, previous studies noted clusters of CD8 þ cells surrounding dystrophin-positive fibres in the treated mdx muscles together with an IgG 2a antibody response 18 and a weak positive dystrophin-specific T-cell ELISPOT in vitro assay. 19 In contrast, when murine full-length dystrophin driven by a muscle-specific promoter was injected into mdx mice, muscle fibres expressing dystrophin persisted for at least 12 weeks and no antibody or CD8 þ T-cell response was noted. 18 In the present study, we delivered both human and murine full-length dystrophin cDNAs under the control of a CMV promoter. The CMV promoter allows the expression of the dystrophin transgene in many cell types, 36 including professional antigen-presenting cells (APCs). While the mechanism of crosspriming seems to be the most likely after intramuscular DNA injection, 37 it is probable that some APC present in the muscle are transfected and antigen expression in these APC primes MHC class I and II responses. We also increased the dose of antigen delivered to the mdx mouse by using the electrotransfer and hyaluronidase pretreatment protocol, Figure 7 Graphs showing the maximum number of dystrophin-positive fibres, after the subtraction of revertants, in transverse sections of TA muscles of microdystrophin mdx transgenic mice and their nontransgenic mdx littermates 8 weeks after injection of full-length human dystrophin plasmid. (a) and (b) represent two separate experiments. Each bar represents the mean7s.e.m. Experiment 1: transgenic n ¼ 10, mdx n ¼ 13. Experiment 2: transgenic n ¼ 5, mdx n ¼ 5. In both experiments, there are significantly more dystrophin-positive fibres in the transgenics compared to mdx littermates. (c) shows a representative Western blot from experiment 2, serum from mdx littermates treated with human dystrophin plasmid exhibit a dystrophin-specific antibody response, whereas serum from similarly treated microdystrophin transgenic mice show no such response. 6C5 is the control antidystrophin monoclonal antibody Dy8/6C5. Blots were simultaneously probed with a monoclonal antibody recognizing metavinculin and vinculin as a loading control.
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A Ferrer et al which is able to achieve higher transfection efficiencies in muscle with a single dose of plasmid DNA 20,25 than previously obtained with three doses of naked plasmid DNA directly injected into the muscle. 18 Using the antibody DysC3750 that recognizes both human and murine dystrophin, we assessed the maximum number of dystrophin-transfected fibres present in the TA muscles from mdx mice electroporated with the human and murine plasmids. Control experiments showed that there was no increase in the number of revertant fibres due to the electrotransfer protocol. Thus we could analyse the number of transfected fibres by subtracting the number of revertant fibres in the uninjected leg from the number of dystrophin-positive fibres in the injected leg. As previously observed, a strong immune response was triggered against human full-length dystrophin in the mdx mouse. Despite the high number of transfected fibres present in the muscle 1 week postelectrotransfer, most fibres were eliminated by 8 weeks and this explains in turn the small level of CD8 þ infiltrate observed at this later time point. However, despite the higher level of murine dystrophin-transfected fibres achieved with electroporation and the possible expression of dystrophin in professional APC, the mdx mouse was again shown to be tolerant to recombinant full-length murine dystrophin. In addition to the presence of similar numbers of transfected fibres at both 1 and 8 weeks, there was no evidence of immune rejection as shown by the lack of specific antibodies to murine dystrophin or the presence of a specific CD8 þ T cells infiltrate in the vicinity of murine dystrophin fibres. However, one mouse did have very few transfected fibres at the 8 week time point and there was a small cluster of CD8 þ T cells surrounding a group of dystrophin-expressing fibres, suggesting that tolerance was broken in this individual animal. This individual was probably responsible for the low-level antibody response seen in the pooled sera from this experiment (Figure 4c ).
Other groups have reported immune responses to murine dystrophin. A decrease in the number of dystrophin-positive fibres 6 weeks after coisogenic myoblast transplantation has been reported. CD8 þ cells surrounding dystrophin-positive fibres were noted, together with a CTL response in vitro against C57Bl10 and murine full-length dystrophin transgenic mdx myoblasts. 38 Myoblast transplantation may involve the presentation of other unfamiliar proteins apart from dystrophin as a result of strain divergence and culture conditions that could contribute to the rejection. However, rejection was avoided by intravenous administration of dystrophin MHCI-specific immunogenic peptides 2 weeks prior to transplantation. Recently, Gilchrist et al 39 have shown a decrease in murine dystrophin expression levels 8 weeks after adenovirus delivery of murine fulllength dystrophin, together with the presence of antibodies against murine dystrophin and a CD4 þ and CD8 þ T-cell infiltrate in the treated tissue. It is difficult to correlate the dystrophin expression levels reported with the number of dystrophin-positive fibres obtained in our study, but it is possible that tolerance was broken due to the greater antigen load achieved with adenovirus versus our electrotransfer protocol. On the other hand, the adenoviral vehicle may have acted as an adjuvant, enhancing the immune response to the transgene.
We believe that the tolerance we observe to murine dystrophin is due to the presence of revertant fibres and other dystrophin isoforms in the absence of the endogenous full-length protein. The expression of dystrophin epitopes developmentally would have ensured that immunoreactive T cells were deleted in the thymus. Each cluster of revertant fibres appears to undergo a specific exon-skipping event and so each cluster expresses a different internally deleted dystrophin at their sarcolemma. 6 The mutation in the mdx mice is in exon 23 so it does not affect the production of dystrophin isoforms apart from the 427 kDa full-length protein. It is possible that the smaller isoforms give rise to tolerance to the epitopes present in the second half of the rod domain and the carboxyl-terminus, whereas revertant fibres are the only source of the amino-terminus and the first half of the rod domain epitopes of dystrophin.
The mdx3cv mouse displays revertant fibres although in smaller numbers than the mdx mouse. 26 However, the promoters for all the dystrophin isoforms are present upstream of the site of mutation and so the mdx3cv is not capable of producing any of the smaller dystrophin isoforms, unlike the mdx mouse. After injection with murine full-length dystrophin plasmid, these mice are also tolerant to the recombinant murine dystrophin as there is no significant decrease in the number of dystrophin-transfected fibres from 1 to 8 weeks.
Since the presence of revertant fibres in the mdx provides tolerance to murine dystrophin following gene transfer, we would predict that for many DMD patients the presence of revertant fibres would similarly prevent the elimination of transfected fibres. In a study performed by Voit et al, 40 up to 30% of DMD patients had some dystrophin expression as detected by Western blots and immunohistochemistry. Other groups have also reported the incidence of revertant fibres in 35-70% of DMD patients. [41] [42] [43] However, the range of dystrophin epitopes expressed in patient revertant fibres is dependent on the nature and position of the mutation in the dystrophin gene. In order to investigate which regions of the dystrophin molecule are required to provide tolerance to de novo expression of full-length dystrophin, we have investigated the transfer of full-length human dystrophin plasmid into mdx transgenic lines expressing internally deleted recombinant dystrophins. These transgenic lines are similar to BMD patients or DMD patients in whom there are large numbers of revertant fibres with exon-skipping events, resulting in the expression of less than 55% of the dystrophin molecule.
Tolerance was seen in most mice when full-length dystrophin was injected into the human minidystrophin transgenic mice (AB2). This was interesting, as these mice had only 55% of the coding region. However, two mice in this study showed isolated clusters of CD8 þ cells around dystrophin-positive fibres and one of them also had very few transfected fibres, which may be a sign of incomplete tolerance. It is important to note that this experiment involved the induction of muscle regeneration by injection of a myotoxic agent in order to increase the efficiency of plasmid delivery by direct injection. Thus the mode of treatment and gene delivery may have contributed to the breakage of tolerance compared to the results observed in the micro-dystrophin experiments. Unfortunately it was not possible to perform the Long-term expression of full-length human dystrophin in mdx mice A Ferrer et al electrotransfer experiments with the minidystrophin line. At the 8 week time point, a high number of intact dystrophin-transfected fibres were present in the muscles from the microdystrophin transgenic line that expresses only 50% of coding region, whereas nearly all transfected fibres had been eliminated in the mdx littermates ( Figure  7a and b) . Thus we conclude that the transgenic mice were tolerant to the full-length protein.
Using an HLA class I humanized mouse model, an HLA-A*0201-restricted immunodominant epitope from human dystrophin has been identified. This epitope present in the spectrin-like repeat 9 of dystrophin is able to elicit CD8 þ CTL responses following intramuscular injection of full-length human dystrophin plasmid. 44 The HLA-A*0201 allele used is expressed in 50% of Caucasian human population. Further studies using other HLA alleles will be of great interest in determining the extent of human dystrophin immune responses in the DMD population. We await publication of the results from the AFM and Transgene Phase I clinical trial for BMD and DMD. 45 Preliminary reports suggest the absence of adverse side effects including a lack of antidystrophin immune responses.
In the mdx mice, at least 5% of the revertant fibres analysed express almost the full-length molecule. 6 A subset of DMD patients present with point mutations (28%) or small deletions (8%), 46 and it is possible that the vast majority of epitopes of the full-length protein will be present in at least some muscle fibres. However, a substantial number of DMD patients (64%) have large genomic deletions and thus any revertant fibre will not express a full range of the epitopes. The location of the mutation in these patients is also of importance, as it will affect the expression of the other isoforms of dystrophin. We have shown that the expression of a very truncated human dystrophin in transgenic mdx mice prevents the cytotoxic elimination of human full-length dystrophintransfected fibres, and this suggests that in many cases the presence of revertant fibres and other isoforms of dystrophin is likely to confer tolerance and prevent serious immune responses in patients undergoing dystrophin gene therapy.
Materials and methods
Dystrophin plasmids
Plasmids were grown in Escherichia coli XL1-Blue cells (Stratagene, La Jolla, USA) and purified using the Endofree plasmid kit from Qiagen (Crawley, UK). LPS contamination levels in all plasmid preparations were less than 0.05 EU per mg of DNA as assessed using Pyrogent 500 turbimetric assay (BioWhittaker, Wokingham, UK). Two human dystrophin plasmids utilizing the strong constitutive CMVIE promoter plus intron were used both expressing full-length human dystrophin (CDF and PTG11025). CDF (15.6 kb) contains the fulllength human dystrophin cDNA and the alternative full-length human dystrophin plasmid; PTG11025 (18.8 kb) was kindly supplied by Serge Braun (Transgene, Strasbourg, France). 18, 19 CDF was used in all the human dystrophin gene transfer studies, except for the experiment with the AB2 transgenic line where PTG11025 was used. The murine dystrophin plasmid, CMVmoDys (16.8 kb), contains the full-length murine dystrophin in the same plasmid backbone as CDF except that the SV40 intron associated with the polyadenylation signal sequences was deleted. The murine full-length cDNA was subcloned from CVAA, which was kindly supplied by Jeff Chamberlain. 29 The noncoding plasmid CMV0 was created by the digestion of CMV lacZ (Clontech, BD Biosciences, Oxford, UK) with NotI and religation to remove the lacZ gene. 47 
Transgenic mouse lines
Two mdx transgenic lines in which recombinant human dystrophin was driven by the human muscle a-skeletal actin (HSA) promoter were used in this study. Transgenic line AB2 (D17-48) expresses human minidystrophin with the deletion of exons 17-48. It expresses 20% of endogenous levels of dystrophin at the sarcolemma and these mice show correction of the myopathic phenotype. 27 The microdystrophin transgenic line (D13-48) has a further deletion of three exons in the rod domain. The microdystrophin construct was compiled from PCR-generated fragments in the laboratory of Professor George Dickson and subcloned into the same vector backbone with the HSA promoter as the previously generated transgenic lines. 27 The new transgenic line was generated by standard microinjection procedures using C57Bl10 X CBA/CA embryos and transgenic mice crossed onto the mdx background for several generations as described previously. 27 
Intramuscular injection of plasmid DNA
All experiments were carried out with a mix of male and female 6-to 19-week-old mice. Mice were kept in minimal disease facilities with food and water ad libitum. Prior to intramuscular injection, mice were anaesthetized with a mixture of fentanyl/fluanisone and midazolam (Hypnorm, Janssen Animal Health, High Wycombe, UK and Hypnovel, Roche, Welwyn Garden City, UK, respectively).
In the minidystrophin (AB2) experiment, direct injection of DNA was carried out in artificially regenerated muscle. At 5 days prior to DNA injection, both TA muscles were treated with 25 ml of an aqueous solution of 1.2% BaCl 2 , a myotoxic agent that induces necrosis and subsequent regeneration of the muscle fibres. 48, 49 After 5 days, one TA received a single dose of 50 mg of PTG11025 plasmid DNA in 25 ml normal saline, injected percutaneously using a 27-gauge needle into the left TA muscle in a proximal to distal direction.
In the other experiments, mice under fentanyl/ fluanisone and midazolam anaesthesia were injected with 10 U (25 ml at 0.4 U/ml) of bovine testes hyaluronidase (Sigma, Pool, UK) 2 h prior to DNA injection and electrotransfer. Mice were anaesthetized by inhalation of isofluorane, the DNA injected and an electrical field of 175 V/cm was applied in 10 20-ms square wave pulses at 1 Hz using a BTX ECM830 electroporator (VWR International, Lutterworth, UK) as described in McMahon et al. 25 The left TA received a single dose of 50 mg of dystrophin plasmid DNA in 25 ml normal saline, injected percutaneously using a 27-gauge needle in a proximal to distal direction. The contralateral TA was either left uninjected or injected with the same quantity of CMV0 and served as a control for dystrophin-positive revertant fibres.
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Collection of samples
Depending on the experiment, samples were colleted at either 1 or 8 weeks after injection of DNA. Under terminal anaesthesia with 0.1 ml pentobarbitol (Euthesate, National Vet Supplies, Stoke on Trent, UK), mice were subjected to cardiac puncture, after which animals were killed by cervical dislocation. The blood was left for a few hours at 41C for the blood clot to retract and it was spun twice at 9000 g for 5 min. For each animal, both TA were excised post-mortem and mounted on cork blocks with a cryoembedding compound (Cryo-M-Bed, Bright, UK). The block was rapidly frozen in isopentane cooled in liquid nitrogen and stored at À701C. Serial sections of 10 mm thickness were cut at 10-12 evenly spaced levels through the block and lifted onto APES-coated glass slides.
Dystrophin immunostains
Slides were air-dried, the endogenous biotin blocked using an avidin/biotin blocking system (Vector Laboratories, Peterborough, UK) and nonspecific binding blocked for 30 min with a 3% solution of dried nonfat milk (Marvel) in PBS/0.05%Tween-20 (PBST). In an initial screen of the microdystrophin transgenic line, sections were stained with either a human dystrophinspecific monoclonal Dy10/12B2 at 1:10 (kindly supplied by Louise Nicholson) or dystrophin rabbit polyclonal DysC3750 at 1:500. 20 For the detection of revertant fibres or transfected dystrophin-positive fibres above the endogenous transgene expression levels, DysC3750 was titred down to a dilution of 1:2000, a level at which this antibody shows no dystrophin detection in the minidystrophin line. 28 Primary antibodies were diluted in PBST plus 1% FCS. Bound antibody was detected with an appropriate biotinylated species specific secondary antibody (Dako, Ely, UK) at 1:500 in PBST, followed by a 30 min incubation with horseradish peroxidaseconjugated streptavidin/biotin complex (ABC-HRP, Vector Laboratories, Peterborough, UK). The enzymatic reaction was visualized by nickel-enhanced diaminobenzidine solution and slides were dehydrated, cleared with xylene and mounted in DPX (VWR International, Lutterworth, UK).
All microscopical analysis was carried out on a Leica DML light microscope and images were recorded using an Image Pro-plus package (Datacell, Maidenhead, UK) and a 3CCD colour camera (JVC). Sections from different levels of each muscle were examined and the highest count of dystrophin-positive fibres was recorded both in the control and injected leg and the maximum number of dystrophin-positive revertant fibres in the control leg was subtracted from the total number of dystrophinpositive fibres in the injected leg.
Immunohistochemical detection of CD8 þ cells
Slides were fixed in acetone for 10 min and nonspecific biotin binding blocked as described above. Sections were incubated with primary antibody rat anti-mouse CD8 (clone no. YTS 169.4, Serotec, Oxford, UK) at 1:500 at room temperature for 1 h. Sections were incubated for an hour with secondary biotinylated rabbit anti-rat antibody (Dako, Ely, UK) at 1:500 in PBST, followed by a 30 min incubation with horseradish peroxidase-conjugated streptavidin/biotin complex (ABC-HRP, Dako, Ely, UK) and the reaction visualized as described above.
For quantitation of CD8 þ cells in each sample, the total number of CD8 þ cells was assessed from three randomly selected fields from the cross-sectional area showing the highest degree of infiltrate. The three microscopic fields at a magnification of Â 100 were captured to a computer using a JVC Ky-F55B 3-CCD camera. The pixel area of dark brown DAB precipitate above a fixed colour threshold was analysed using the SigmaScan Pro version 5.0.0 image analysis software (SPSS, Birmingham, UK). A linear regression curve of the number of manually counted CD8 þ cells versus the pixel area they occupy in the microscopic field was obtained for each experiment (r 2 ¼ 0.81-0.95). For each sample, the average number of CD8 þ cells per random field was extrapolated from the standard curve and expressed as the number of CD8 þ cells per mm 2 . The results are presented as the increased number of CD8 þ cells in the treated muscle compared to the untreated muscle, thus demonstrating possible specific increases above the endogenous CD8 þ counts in dystrophic muscle. 50 
Western blot analysis of humoral immune response
Skeletal muscle from C57BL10, mdx, minidystrophin, microdystrophin and AD17 (a transgenic mouse line that overexpresses full-length human dystrophin) 27 was ground to a powder in liquid nitrogen and resuspended in Tris-buffered saline with 1% NP40, 0.5%. sodium deoxycholate, 0.1% SDS and protease inhibitors (RIPA buffer 29 ) . After a 5 min centrifugation at 13 000 rpm in a bench centrifuge to pellet myofilaments, the supernatants were solubilized in 10% SDS sample buffer and fractionated on a 6% polyacrylamide gel as described previously. 27, 28 Proteins were transferred to PVDF membrane and equality of protein transfer confirmed by staining the membrane with a 0.1% solution of amido black. For the analysis of humoral immune responses, strips of membrane from blots containing paired tracks of either AD17 and mdx or C57BL10 and mdx extracts were prepared. Methanol prewetted membranes were incubated with a 5% solution of dried milk (Marvel) in TBS containing 0.05% of Tween-20 (TBST) prior to incubation with either control dystrophin monoclonal antibody Dy8/6C5 (a kind gift from Louise Nicholson, Newcastle, UK) at 1/100 dilution in TBST or 1/20 dilution of mouse serum in 2% Marvel in TBST. All strips were simultaneously probed with a monoclonal antibody against vinculin at 1/400 dilution in TBST (V9131, Sigma, Poole, UK). This was chosen as the loading control as vinculin occupies a subsarcolemmal position similar to dystrophin. Secondary antibody goat anti-mouse IgG conjugated to HRP (Biorad, Hertfordshire, UK) was used at a dilution of 1:10 000. Antibodies were detected by enhanced chemiluminescence (ECL; Amersham Biosciences, Chalfont St Giles, UK). The blots were exposed to blue sensitive X-ray film (GRI, Braintree, UK) and developed using an Automatic X-Ray Film (Processor X-ograph Imaging Systems, Malmesbury, UK).
Statistical analysis
With normally distributed data, statistical analysis was conducted by Student's t-test or one-way ANOVA, followed by multiple paired comparisons as appropriate.
Long-term expression of full-length human dystrophin in mdx mice A Ferrer et al For nonparametric data, statistical analysis was conducted by Mann-Whitney rank-sum test or ANOVA on ranks, followed by multiple paired comparisons as appropriate. Groups were considered statistically significant when Po0.05. The tests were carried out using Sigma-Stat from Jandel Scientific (Germany).
